Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-transfected [correction of tranfected] Chinese hamster ovary cells

European Journal of Pharmacology
F L FierensG Vauquelin


Binding of the non-peptide angiotensin II AT1 antagonist [3H](2-ethoxy-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]- H-benzimidazoline-7-carboxylic acid ([3H]candesartan) to human angiotensin II AT1 receptor-transfected Chinese hamster ovary (CHO-AT1) cells was inhibited to the same extent by angiotensin II and non-peptide angiotensin II AT1 antagonists. No binding was observed in control CHO-K1 cells. Dissociation was slow (k(-1) = 0.0010+/-0.0001 min(-1)) after removal of the free [3H]candesartan but increased 5-fold upon addition of supramaximal concentrations of angiotensin II AT1 antagonists. Angiotensin II responses recovered equally slow from candesartan-pretreatment. When washed and further incubated, these angiotensin II responses also recovered more rapidly in the presence of 2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphen yl-4-yl)methyl]imidazole (losartan), indicating that unlabelled ligands prevented reassociation. [3 H]candesartan saturation binding experiments required a long time to reach equilibrium. Therefore, the equilibrium dissociation constant (Kd = 51+/-8 pM) was calculated from the association and dissociation rate constants. Our findings indicate that the insurmountable nature of ca...Continue Reading


Mar 31, 1992·Biochemical and Biophysical Research Communications·S S KakarJ D Neill
Feb 1, 1991·Trends in Pharmacological Sciences·P B TimmermansW F Herblin
Jul 7, 1983·Journal of Theoretical Biology·A Gero
Dec 1, 1995·The Journal of Biological Chemistry·K NodaS S Karnik
Jan 1, 1995·Journal of Cardiovascular Pharmacology·S MochizukiA Tomiyama
Oct 1, 1994·Trends in Pharmacological Sciences·M J RobertsonP Leff
Aug 1, 1996·Trends in Pharmacological Sciences·E Kostenis, K Mohr
Jan 14, 1997·European Journal of Pharmacology·M OjimaK Nishikawa

❮ Previous
Next ❯


Aug 28, 2010·Naunyn-Schmiedeberg's Archives of Pharmacology·Peter HeuslerDidier Cussac
Apr 27, 2001·Biochemical Pharmacology·F L FierensaG Vauquelin
Sep 18, 2002·Biochemical Pharmacology·Ilse VerheijenGeorges Vauquelin
Dec 31, 2002·European Journal of Pharmacology·Catherina Caballero-GeorgeArnold Vlietinck
Jul 8, 1999·European Journal of Pharmacology·F L FierensG Vauquelin
Mar 4, 2000·Lancet·M Burnier, H R Brunner
Mar 14, 2002·Regulatory Peptides·Minh Tam LeGeorges Vauquelin
Sep 2, 2004·Nature Reviews. Drug Discovery·David C Swinney
Feb 7, 2003·Fundamental & Clinical Pharmacology·G VauquelinP M L Vanderheyden
Jul 1, 2006·Future Cardiology·Robert S McKelvie
Jan 19, 2012·Clinical and Experimental Hypertension : CHE·Hiroshi HasegawaIssei Komuro
Oct 6, 2006·Expert Opinion on Pharmacotherapy·Robert S McKelvie
Mar 29, 2018·Clinical and Experimental Hypertension : CHE·Di ZhaoPingshuan Dong
Aug 25, 2017·British Journal of Pharmacology·Georges Vauquelin
Jul 26, 2002·Journal of Human Hypertension·A H Gradman
Feb 3, 2004·The Journal of Biological Chemistry·Takanobu TakezakoSadashiva S Karnik
Feb 15, 2001·Circulation·M Burnier
Mar 1, 2001·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Georges VauquelinPatrick Ml Vanderheyden
Mar 1, 2001·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Georges VauquelinPatrick Ml Vanderheyden
Apr 23, 2002·Journal of the Renin-angiotensin-aldosterone System : JRAAS·P M VanderheydenG Vauquelin
Aug 26, 2009·Fundamental & Clinical Pharmacology·M WennerbergGeorges Vauquelin
Oct 1, 2010·British Journal of Pharmacology·Georges Vauquelin, Steven J Charlton
Apr 8, 2006·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·Georges VauquelinIsabelle Van Liefde
May 3, 2016·British Journal of Clinical Pharmacology·Georges Vauquelin
Nov 24, 2006·American Journal of Physiology. Cell Physiology·Julia L CookRichard N Re
Jun 19, 2007·The Journal of Pharmacology and Experimental Therapeutics·Erik LindströmGeorges Vauquelin
Aug 17, 2002·The Journal of Pharmacology and Experimental Therapeutics·Marc P MaillardMichel Burnier
Jan 18, 2013·Journal of Hypertension·Maarten A D H Schalekamp, A H Jan Danser
Nov 6, 2012·Cardiovascular Therapeutics·Joel M Neutel, David H G Smith
Jan 26, 2016·British Journal of Pharmacology·Georges VauquelinDavid C Swinney
Oct 31, 2001·Blood Pressure. Supplement·T Unger
Jul 9, 2010·Fundamental & Clinical Pharmacology·Marie WennerbergGeorges Vauquelin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.


Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.